Advertisement
Advertisement
RZLT
Rezolute, Inc. Common Stock (NV)
4.69
USDSponsored
-0.01
-0.21%
Aug 07, 15:59 UTC -4
Closed
After-Market
4.67
-0.02
-0.32%
RZLT Earnings Reports
Positive Surprise Ratio
RZLT beat 18 of 28 last estimates.
64%
Next Report
Date of Next Report
Sep 15, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.15
Implied change from Q3 26 (Revenue/ EPS)
--
/-6.25%
Implied change from Q4 25 (Revenue/ EPS)
--
/-42.31%
Rezolute, Inc. Common Stock (NV) earnings per share and revenue
On May 12, 2026, RZLT reported earnings of -0.16 USD per share (EPS) for Q3 26, beating the estimate of -0.18 USD, resulting in a 12.33% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.91% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.15 USD, with revenue projected to reach -- USD, implying an decrease of -6.25% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Rezolute, Inc. Common Stock (NV)'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Rezolute, Inc. Common Stock (NV) reported EPS of -$0.16, beating estimates by 12.33%, and revenue of $0.00, 0% as expectations.
How did the market react to Rezolute, Inc. Common Stock (NV)'s Q3 2026 earnings?
The stock price moved up 0.91%, changed from $3.30 before the earnings release to $3.33 the day after.
When is Rezolute, Inc. Common Stock (NV) expected to report next?
The next earning report is scheduled for Sep 15, 2026.
What are the forecasts for Rezolute, Inc. Common Stock (NV)'s next earnings report?
Based on --
analysts, Rezolute, Inc. Common Stock (NV) is expected to report EPS of -$0.15 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement